Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Research & Development (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Research & Development for 5 consecutive years, with $7.8 million as the latest value for Q1 2026.

  • For Q1 2026, Research & Development fell 15.39% year-over-year to $7.8 million; the TTM value through Mar 2026 reached $31.4 million, down 7.3%, while the annual FY2025 figure was $32.8 million, 3.82% down from the prior year.
  • Research & Development hit $7.8 million in Q1 2026 for Phathom Pharmaceuticals, up from $7.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $19.0 million in Q3 2022 and bottomed at $7.0 million in Q3 2025.
  • Average Research & Development over 5 years is $11.5 million, with a median of $9.4 million recorded in 2024.
  • Year-over-year, Research & Development tumbled 42.21% in 2024 and then rose 23.05% in 2025.
  • Phathom Pharmaceuticals' Research & Development stood at $15.9 million in 2022, then fell by 16.0% to $13.4 million in 2023, then tumbled by 35.92% to $8.6 million in 2024, then decreased by 12.7% to $7.5 million in 2025, then rose by 3.71% to $7.8 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $7.8 million, $7.5 million, and $7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.